1. Gastrointestinal Disorders Therapeutics Market to 2018 - Novel
Agents Targeting Irritable Bowel Syndrome (IBS), Chronic
Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate
the Market
Report Details:
Published:November 2012
No. of Pages: 171
Price: Single User License – US$3500
Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel
Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market
Summary
GBI Research, the leading business intelligence provider, has released its latest research,
“Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel
Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the
Market”, which provides insights into the gastrointestinal disorders therapeutics market until 2018.
The report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GBI Research’s team of industry experts. It provides
in-depth analysis of the major diseases, comprising IBS, constipation, Crohn’s disease, UC,
Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). The report also gives
the size of the generic share in the global gastrointestinal disorders therapeutics market and in
those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns
and geographical distribution. Additionally, it includes insights into the R&D product pipeline and
explores the competitive landscape, looking at major players and including analysis of M&A,
licensing agreements and co-development deals that have taken place in the past two years.
GBI Research’s analysis shows that the gastrointestinal disorders therapeutics market is set to
witness high generic competition in the forecast period, as major drugs used in the treatment of
the aforementioned disorders are set to expire, resulting in declining revenues and allowing
generics to enter the market. Nevertheless, the market will witness steady growth due to the
anticipated entry of innovative new drugs in the near future. Furthermore, strong R&D in IBS,
constipation, Crohn’s disease and UC remains a key market driver.

2. Scope
- Data and analysis for the gastrointestinal disorders therapeutics markets in the leading
geographies: the US; the top five countries of Europe, comprising the UK, Germany, France, Italy
and Spain; Japan; and an overview of India, China and Australia
- Annualized market data for the gastrointestinal disorders therapeutics market from 2004 to 2010
and forecast to 2018
- Market data for the geographical and therapeutic landscapes, including size, share, annual cost
of therapy, sales volume and treatment usage patterns for the diseased population, diagnosis
population and prescription population
- Generic share in the global market and for each indication
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global market, looking at key companies such as AstraZeneca,
Takeda, Johnson & Johnson , Eisai, Abbott, Shire and Salix
- Key M&A activity and licensing agreements that took place between 2010 and 2012
Reasons to buy
- Align product portfolios to the markets with high growth potential
- Build effective strategies to launch pipeline products by identifying potential geographies
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio
gaps
- Develop key strategic initiatives by studying top competitors’ key strategies
- Device a more tailored country strategy by understanding the key drivers, barriers and market
potential for each indication
- Develop market-entry and market-expansion strategies by identifying the markets poised for
strong growth
- Reinforce R&D pipelines by identifying new target mechanisms producing safer and more
efficacious FIC molecules
Get your copy of this report @
http://www.reportsnreports.com/reports/202050-gastrointestinal-disorders-therapeutics-market-to-2018-novel-
agents-targeting-irritable-bowel-syndrome-ibs-chronic-constipation-cc-and-ulcerative-colitis-uc-to-reinvigorate-the-
market.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 12
2 Gastrointestinal Disorders Therapeutics Market - Introduction 15
2.1 Overview 15
3 Global Gastrointestinal Disorders Therapeutics Market - Market Characterization 16
3.1 Market Forecasts 16

3. 3.1.1 Branded and Generic Global Market Share 18
3.1.2 Annual Cost of Treatment 19
3.1.3 Treatment Usage Patterns 20
3.2 Drivers and Restraints for the Global Gastrointestinal Disorders Therapeutics Market 22
3.2.1 Market Drivers 22
3.2.2 Market Restraints 23
4 Gastrointestinal Disorders Therapeutics Market - Geographical Landscape 24
4.1 Revenue Analysis by Geography 24
4.2 The US 24
4.2.1 Revenue 24
4.2.2 Annual Cost of Treatment 26
4.2.3 Treatment Usage Patterns 27
4.3 Top Five Countries of Europe 29
4.3.1 Revenue 29
4.3.2 Revenue by Country 30
4.3.3 Annual Cost of Treatment 32
4.3.4 Treatment Usage Patterns 33
4.4 Japan 35
4.4.1 Revenue 35
4.4.2 Annual Cost of Treatment 37
4.4.3 Treatment Usage Patterns 38
4.5 Gastrointestinal Disorders Therapeutics Market India-Overview 40
4.5.1 Epidemiology 40
4.5.2 Clinical Trials 41
4.5.3 Drivers and Restraints 41
4.6 Gastrointestinal Disorders Therapeutics Market Australia-Overview 42
4.6.1 Epidemiology 42
4.6.2 Clinical Trials 43
4.6.3 Drivers and Restraints 43
4.7 Gastrointestinal Disorders Therapeutics Market China-Overview 44
4.7.1 Epidemiology 44
4.7.2 Clinical Trials 45
4.7.3 Drivers and Restraints 45
5 Global Gastrointestinal Disorders Therapeutics Market - Therapeutic Landscape 46
5.1 Global Irritable Bowel Syndrome Therapeutics Market Forecasts 46
5.1.1 Introduction 46
5.1.2 Treatment Flow Algorithm 47
5.1.3 Revenue 48
5.1.4 Revenue by Country 49
5.1.5 Branded vs. Generic Market Share 51
5.1.6 Annual Cost of Treatment 52
5.1.7 Treatment Usage Patterns 53

4. 5.2 Drivers and Restraints for the Irritable Bowel Syndrome Therapeutics Market 55
5.2.1 Drivers for the Irritable Bowel Syndrome Therapeutics Market 55
5.2.2 Restraints for the Irritable Bowel Syndrome Therapeutics Market 55
5.3 Global Constipation Therapeutics Market Forecasts 56
5.3.1 Introduction 56
5.3.2 Treatment Flow Algorithm 57
5.3.3 Revenue 58
5.3.4 Revenue Analysis by Country 59
5.3.5 Branded vs. Generic Market Share 61
5.3.6 Annual Cost of Treatment 62
5.3.7 Treatment Usage Patterns 63
5.4 Drivers and Restraints for the Constipation Therapeutics Market 65
5.4.1 Drivers for Constipation Therapeutics Market 65
5.4.2 Restraints for Constipation Therapeutics Market 65
5.5 Global Crohn’s Disease Therapeutics Market Forecasts 66
5.5.1 Introduction 66
5.5.2 Treatment Flow Algorithm 67
5.5.3 Revenue 68
5.5.4 Revenue by Country 69
5.5.5 Branded vs. Generic Market Share 71
5.5.6 Annual Cost of Treatment 72
5.5.7 Treatment Usage Patterns 73
5.6 Drivers and Restraints for the Crohn’s Disease Therapeutics Market 75
5.6.1 Drivers for the Crohn’s Disease Therapeutics Market 75
5.6.2 Restraints for the Crohn’s Disease Therapeutics Market 75
5.7 Global Ulcerative Colitis Therapeutics Market Forecasts 76
5.7.1 Introduction 76
5.7.2 Treatment Flow Algorithm 77
5.7.3 Revenue 78
5.7.4 Revenue by Country 79
5.7.5 Branded vs. Generic Market Share 81
5.7.6 Annual Cost of Treatment 82
5.7.7 Treatment Usage Patterns 83
5.8 Drivers and Restraints for the Ulcerative Colitis Therapeutics Market 85
5.8.1 Drivers for the Ulcerative Colitis Therapeutics Market 85
5.8.2 Restraints for the Ulcerative Colitis Therapeutics Market 85
5.9 Global Gastroesophageal Reflux Disease Therapeutics Market Forecasts 86
5.9.1 Introduction 86
5.9.2 Treatment Flow Algorithm 87
5.9.3 Revenue 89
5.9.4 Revenue by Country 91
5.9.5 Branded vs. Generic Market Share 93

5. 5.9.6 Annual Cost of Treatment 94
5.9.7 Treatment Usage Patterns 95
5.10 Drivers and Restraints for the Gastroesophageal Reflux Disease Therapeutics Market 97
5.10.1 Drivers for the Gastroesophageal Reflux Disease Therapeutics Market 97
5.10.2 Restraints for the Gastroesophageal Reflux Disease Therapeutics Market 97
5.11 Global Peptic Ulcer Disease Therapeutics Market Forecasts 98
5.11.1 Introduction 98
5.11.2 Treatment Flow Algorithm 99
5.11.3 Revenue 100
5.11.4 Revenue Analysis by Country 102
5.11.5 Generic vs. Branded Market Share 104
5.11.6 Annual Cost of Treatment 105
5.11.7 Treatment Usage Patterns 106
5.12 Drivers and Restraints for the Peptic Ulcer Disease Therapeutics Market 108
5.12.1 Drivers for Peptic Ulcer Disease Therapeutics Market 108
5.12.2 Restraints for Peptic Ulcer Disease Therapeutics Market 108
6 Global Gastrointestinal Disorders Therapeutics Market - Pipeline Analysis 109
6.1 Summary 109
6.2 Research and Development Pipeline by Phase 109
6.3 Research and Development Pipeline by Indication 110
6.4 Irritable Bowel Syndrome: Research and Development Pipeline 111
6.4.1 Pipeline by Phase 111
6.5 Constipation: Research and Development Pipeline 112
6.5.1 Research and Development Pipeline by Phase 112
6.6 Crohn’s Disease: Research and Development Pipeline 113
6.6.1 Research and Development Pipeline by Phase 113
6.7 Ulcerative Colitis: Research and Development Pipeline 114
6.7.1 Research and Development Pipeline by Phase 114
6.8 Gastroesophageal Reflux Disease: Research and Development Pipeline 115
6.8.1 Research and Development Pipeline by Phase 115
6.9 Peptic Ulcer Disease: Research and Development Pipeline 116
6.9.1 Research and Development Pipeline by Phase 116
6.10 Promising Pipeline Molecules 117
6.10.1 Linzess (linaclotide) 118
6.10.2 Xifaxan (rifaximin) 120
6.10.3 Relistor (methylnaltrexone) 121
6.10.4 Humira (adalimumab) 123
6.10.5 Uceris (budesonide) 123
6.10.6 Plecanatide 124
6.10.7 Vedolizumab (MLN0002) 125
6.10.8 Naloxegol (NKTR-118) 126
6.10.9 Simponi (golimumab) 127

6. 6.10.10 Asimadoline 128
6.10.11 Traficet-EN (GSK-1605786) 129
6.10.12 Cobiprostone 130
7 Global Gastrointestinal Disorders Therapeutics Market - Competitive Landscape 131
7.1 Market Share Analysis 131
7.2 Profiles of Major Companies 132
7.2.1 AstraZeneca 132
7.2.2 Takeda Pharmaceutical Company 133
7.2.3 Johnson & Johnson 135
7.2.4 Eisai Co., Ltd. 136
7.2.5 Abbott Laboratories 137
7.2.6 Shire 138
7.2.7 Salix Pharmaceuticals 139
8 Global Gastrointestinal Disorders Therapeutics Market - Strategic Consolidations 142
8.1 Overview 142
8.2 Mergers and Acquisitions 143
8.2.1 Major Mergers and Acquisitions Deals 143
8.2.2 Segmentation by Geography 146
8.2.3 Segmentation by Deal Value 147
8.2.4 Segmentation by Year 148
8.3 Licensing Deals 149
8.3.1 Major Licensing Deals 149
8.3.2 Segmentation by Geography 152
8.3.3 Segmentation by Deal Value 153
8.3.4 Segmentation by Year 154
8.4 Co-development/Co-marketing Deals 155
8.4.1 Major Co-development/Co-marketing Deals 155
8.4.2 Segmentation by Geography 158
8.4.3 Segmentation by Deal Value 159
8.4.4 Segmentation by Year 160
9 Gastrointestinal Disorders Therapeutics Market - Appendix 161
9.1 Abbreviations 161
9.2 Market Definitions 162
9.3 Bibliography 162
9.4 Research Methodology 166
9.4.1 Secondary Research 166
9.4.2 Primary Research 166
9.4.3 Expert Panel Validation 167
9.4.4 Section-wise Research Methodology 167
9.5 Therapeutic Landscape 167
9.5.2 Market Size by Geography 169
9.6 Geographical Landscape 170

7. 9.7 Pipeline Analysis 170
9.8 Competitive Landscape 170
9.9 Strategic Consolidations 170
9.10 Contact Us 170
9.11 Disclaimer 171
1.1 List of Tables
Table 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004–2011 16
Table 2: Gastrointestinal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn),
2011–2018 16
Table 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),
2004–2011 19
Table 4: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),
2011–2018 19
Table 5: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern
(Million), 2004–2011 20
Table 6: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern
(Million), 2011–2018 21
Table 7: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004–2011 24
Table 8: Gastrointestinal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn),
2011–2018 24
Table 9: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),
2004–2011 26
Table 10: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),
2011–2018 26
Table 11: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns
(‘000), 2004–2011 27
Table 12: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns
(‘000), 2011–2018 28
Table 13: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
($bn), 2004–2011 29
Table 14: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
Forecast, ($bn), 2011–2018 29
Table 15: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
by Country ($bn), 2004–2011 30
Table 16: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
Forecasts by Country ($bn), 2011–2018 31
Table 17: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual
Cost of Treatment ($), 2004–2011 32
Table 18: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual
Cost of Treatment ($), 2011–2018 32
Table 19: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe,

8. Treatment Usage Patterns (Million), 2004–2011 33
Table 20: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe,
Treatment Usage Patterns (Million), 2011–2018 34
Table 21: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004–2011 35
Table 22: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn),
2011–2018 35
Table 23: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),
2004–2011 37
Table 24: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),
2011–2018 37
Table 25: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns
(‘000), 2004–2011 38
Table 26: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns
(‘000), 2011–2018 39
Table 27: Gastrointestinal Disorders Therapeutics Market, Diseased Population (‘000), India, 2011
40
Table 28: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, India, 2012 41
Table 29: Gastrointestinal Disorders Therapeutics Market, Diseased Population (‘000), Australia,
2011 42
Table 30: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, Australia, 2012 43
Table 31: Gastrointestinal Disorders Therapeutics Market, Diseased Population (‘000), China,
2011 44
Table 32: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, China, 2012 45
Table 33: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004–2011 48
Table 34: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecasts ($m),
2011–2018 48
Table 35: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m),
2004–2011 49
Table 36: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecast by Country
($m), 2011–2018 50
Table 37: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($),
2004–2011 52
Table 38: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($),
2011–2018 52
Table 39: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns
(‘000), 2004–2011 53
Table 40: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns
(‘000), 2011–2018 54
Table 41: Constipation Therapeutics Market, Global, Revenue ($m), 2004–2011 58
Table 42: Constipation Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 58
Table 43: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 59
Table 44: Constipation Therapeutics Market, Global, Revenue Forecasts by Country ($m),

9. 2011–2018 60
Table 45: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 62
Table 46: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2011–2018 62
Table 47: Constipation Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2004–2011
63
Table 48: Constipation Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2011–2018
64
Table 49: Crohn’s Disease Therapeutics Market, Global, Revenue ($m), 2004–2011 68
Table 50: Crohn’s Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 68
Table 51: Crohn’s Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 69
Table 52: Crohn’s Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m),
2011–2018 70
Table 53: Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($),
2004–2011 72
Table 54: Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($),
2011–2018 72
Table 55: Crohn’s Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004–2011
73
Table 56: Crohn’s Disease Therapeutics Market, Global, Treatment Usage Patterns, 2011–2018
74
Table 57: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004–2011 78
Table 58: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 78
Table 59: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004–2011
79
Table 60: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecast by Country ($m),
2011–2018 80
Table 61: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($),
2004–2011 82
Table 62: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($),
2011–2018 82
Table 63: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000),
2004–2011 83
Table 64: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000),
2011–2018 84
Table 65: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m),
2004–2011 89
Table 66: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts
($m), 2011–2018 89
Table 67: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country
($m), 2004–2011 91
Table 68: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts by
Country ($m), 2011–2018 92

10. Table 69: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of
Treatment ($), 2004–2011 94
Table 70: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of
Treatment ($), 2011–2018 94
Table 71: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage
Patterns (‘000), 2004–2011 95
Table 72: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage
Patterns (‘000), 2011–2018 96
Table 73: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004–2011 100
Table 74: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts ($m),
2011–2018 100
Table 75: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m),
2004–2011 102
Table 76: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m),
2011–2018 103
Table 77: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($),
2004–2011 105
Table 78: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($),
2011–2018 105
Table 79: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns (‘000),
2004–2011 106
Table 80: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns (‘000),
2011–2018 107
Table 81: Gastrointestinal Disorders Therapeutics Market, Global, NDA-filed Molecules, 2012 117
Table 82: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase III Molecules,
2012 117
Table 83: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase II Molecules,
2012 117
Table 84: Gastrointestinal Disorders Therapeutics Market, Global, Major M&A Deals, 2010–Mid
2012 143
Table 85: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography,
2010–Mid-2012 146
Table 86: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%),
2010–Mid-2012 147
Table 87: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year, 2010–Mid-
2012 148
Table 88: Gastrointestinal Disorders Therapeutics Market, Global, Major Licensing Deals,
2010–Mid-2012 149
Table 89: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography,
2010–Mid-2012 152
Table 90: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value,
2010–Mid 2012 153

11. Table 91: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year,
2010–Mid-2012 154
Table 92: Gastrointestinal Disorders Therapeutics Market, Global, Major Co-development/Co-
Marketing Deals, 2010–Mid-2012 155
Table 93: Gastrointestinal Disorders Therapeutics Market, Global, Co-development/Marketing
Deals by Geography, 2010–Mid-2012 158
Table 94: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value,
2010–Mid-2012 159
Table 95: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year,
2010–Mid-2012 160
1.2 List of Figures
Figure 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004–2018 16
Figure 2: Gastrointestinal Disorders Therapeutics Market, Global, Branded and Generic Market
Share (%), 2011 18
Figure 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),
2004–2018 19
Figure 4: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern
(Million), 2004–2018 20
Figure 5: Gastrointestinal Disorders Therapeutics Market, Global, Market Drivers and Restraints
22
Figure 6: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004–2018 24
Figure 7: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),
2004–2018 26
Figure 8: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns
(‘000), 2004–2018 27
Figure 9: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
($bn), 2004–2018 29
Figure 10: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe,
Revenue by Country ($bn), 2004–2018 30
Figure 11: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual
Cost of Treatment ($), 2004–2018 32
Figure 12: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe,
Treatment Usage Patterns (Million), 2004–2018 33
Figure 13: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004–2018 35
Figure 14: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),
2004–2018 37
Figure 15: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns
(‘000), 2004–2018 38
Figure 16: Irritable Bowel Syndrome Therapeutics Market, Global, Breakdown of Irritable Bowel
Syndrome Subtypes(%), 2012 46
Figure 17: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Flow Algorithm for

12. Irritable Bowel Syndrome 47
Figure 18: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004–2018 48
Figure 19: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m),
2004–2018 49
Figure 20: Irritable Bowel Syndrome Therapeutics Market, Global, Branded vs. Generic Market
Share (%), 2011 51
Figure 21: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($),
2004–2018 52
Figure 22: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns
(‘000), 2004–2018 53
Figure 23: Irritable Bowel Syndrome Therapeutics Market, Global, Market Drivers and Restraints
55
Figure 24: Constipation Therapeutics Market, Global, Treatment Flow Algorithm for Constipation
57
Figure 25: Constipation Therapeutics Market, Global, Revenue ($m), 2004–2018 58
Figure 26: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004–2018 59
Figure 27: Constipation Therapeutics Market, Global, Branded vs. Generic Market Share (%),
2011 61
Figure 28: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2018 62
Figure 29: Constipation Therapeutics Market, Global, Treatment Usage Patterns (‘000),
2004–2018 63
Figure 30: Constipation Therapeutics Market, Global, Market Drivers and Restraints 65
Figure 31: Crohn’s Disease Therapeutics Market, Global, Treatment Flow Algorithm for Crohn’s
Disease 67
Figure 32: Crohn’s Disease Therapeutics Market, Global, Revenue ($m), 2004–2018 68
Figure 33: Crohn’s Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–2018
69
Figure 34: Crohn’s Disease Therapeutics Market, Global, Branded vs. Generic Market Share (%),
2011 71
Figure 35: Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($),
2004–2018 72
Figure 36: Crohn’s Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004–2018
73
Figure 37: Crohn’s Disease Therapeutics Market, Global, Market Drivers and Restraints 75
Figure 38: Ulcerative Colitis Therapeutics Market, Global, Treatment Flow Algorithm for Ulcerative
Colitis 77
Figure 39: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004–2018 78
Figure 40: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004–2018
79
Figure 41: Ulcerative Colitis Therapeutics Market, Global, Branded vs. Generic Market Share (%),
2011 81
Figure 42: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($),

13. 2004–2018 82
Figure 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000),
2004–2018 83
Figure 44: Ulcerative Colitis Therapeutics Market, Global, Market Drivers and Restraints 85
Figure 45: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Flow
Algorithm for Self and Primary-care Treatment 87
Figure 46: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Flow
Algorithm for Secondary-care Treatment 88
Figure 47: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m),
2004–2018 89
Figure 48: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country
($m), 2004–2018 91
Figure 49: Gastroesophageal Reflux Disease Therapeutics Market, Global, Branded vs. Generic
Market Share (%), 2011 93
Figure 50: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of
Treatment ($), 2004–2018 94
Figure 51: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage
Patterns (‘000), 2004–2018 95
Figure 52: Gastroesophageal Reflux Disease Therapeutics Market, Market Drivers and Restraints
97
Figure 53: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Flow Algorithm 99
Figure 54: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004–2018 100
Figure 55: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m),
2004–2018 102
Figure 56: Peptic Ulcer Disease Therapeutics Market, Global, Generic vs. Branded Market Share
(%) 104
Figure 57: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($),
2004–2018 105
Figure 58: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns (‘000),
2004–2018 106
Figure 59: Peptic Ulcer Disease Therapeutics Market, Market Drivers and Restraints 108
Figure 60: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Phase, (%), 2012
109
Figure 61: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Indication, (%),
2012 110
Figure 62: Gastrointestinal Disorders Therapeutics Market, Global, IBS Pipeline by Phase, (%),
2012 111
Figure 63: Gastrointestinal Disorders Therapeutics Market, Global, Constipation Pipeline by
Phase, (%), 2012 112
Figure 64: Gastrointestinal Disorders Therapeutics Market, Global, Crohn’s Disease Pipeline by
Phase, (%), 2012 113
Figure 65: Gastrointestinal Disorders Therapeutics Market, Global, Ulcerative Colitis Pipeline by

14. Phase, (%), 2012 114
Figure 66: Gastrointestinal Disorders Therapeutics Market, Global, GERD Pipeline by Phase, (%),
2012 115
Figure 67: Gastrointestinal Disorders Therapeutics Market, Global, Peptic Ulcer Disease Pipeline
by Phase, (%), 2012 116
Figure 68: Gastrointestinal Disorders Therapeutics Market, Global, Market Share by Company, %,
2011 131
Figure 69: Gastrointestinal Disorders Therapeutics Market, AstraZeneca, SWOT Analysis 132
Figure 70: Gastrointestinal Disorders Therapeutics Market, Takeda Pharmaceutical Company,
SWOT Analysis 134
Figure 71: Gastrointestinal Disorders Therapeutics Market, Johnson & Johnson, SWOT Analysis
135
Figure 72: Gastrointestinal Disorders Therapeutics Market, Eisai Company Limited, SWOT
Analysis 136
Figure 73: Gastrointestinal Disorders Therapeutics Market, Abbott Laboratories, SWOT Analysis
137
Figure 74: Gastrointestinal Disorders Therapeutics Market, Shire, SWOT Analysis 138
Figure 75: Gastrointestinal Disorders Therapeutics Market, Salix Pharmaceuticals, SWOT
Analysis 140
Figure 76: Gastrointestinal Disorders Therapeutics Market, Deals by Type, 2010–Mid-2012 142
Figure 77: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography,
2010–Mid-2012 146
Figure 78: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%),
2010–Mid-2012 147
Figure 79: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year,
2010–Mid-2012 148
Figure 80: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography,
2010–Mid-2012 152
Figure 81: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m),
2010–Mid-2012 153
Figure 82: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year,
2010–Mid-2012 154
Figure 83: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals by
Geography, 2010–Mid-2012 158
Figure 84: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m),
2010–Mid-2012 159
Figure 85: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals by
Year, 2010–Mid 2012 160
Figure 86: GBI Research Market Forecasting Model 169
Contact: sales@reportsandreports.com for more information.